Register to receive a free U.S. Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices Market report synopsis and brochure
Botox maker, Allergan plc, has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products.
Allergan made an upfront payment of $90 million and could make additional payments related to the achievement of development and commercialization milestones. With this acquisition, Allergan has added Anterios’ proprietary NDS platform delivery technology focused on the local, targeted delivery of neurotoxins through the skin.
Allergan has also gained worldwide rights to ANT-1207, a topical formulation botulinum toxin type A which is being developed for the treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.
With this acquisition, Allergan is looking to strengthen its position in the worldwide market for neuromodulators. Allergan is currently evaluating Botox, which generated sales of $1.3 billion in the first nine months of 2015, for cosmetic indications like treating forehead lines, masseter hypertrophy and platysma bands and therapeutic indications like osteoarthritis and depression.
A topical formulation would provide patients with a non-invasive option for their dermatologic and aesthetic conditions. Although Botox is more widely used for cosmetic applications, the drug does have several other current indications, including for treatment of eyelid spasms, migraines, and urinary incontinence. Currently, Botox is in phase 2 studies for both depression and osteoarthritis.
Allergan is testing Botox for treatment of osteoarthritis, using change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score.
For Further Information
More on the botox market in the U.S. can be found in the report published by iData entitled U.S. Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices Market. The market segments covered in this report include botulinum toxin A market, dermal filler market, augmentation and reconstructive implant market, fat-reduction device market, and aesthetic laser and light therapy market.
The iData series on Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices covers the U.S., Australia, Japan, South Korea and 15 countries in Europe encompassing Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.
To find out more about botox market data or procedure data, register online or email us at [email protected] for a U.S. Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices Market report brochure and synopsis.
About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.
Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.